As we accrue more data on the benefits and harms from cancer screening, it is clear that the benefits do not always exceed the harms. This imbalance is particularly at issue in lung cancer screening by low-dose computed tomography (LDCT), for which 1 randomized clinical trial found a mortality benefit in high-risk smokers and ex-smokers,1 but 3 other randomized clinical trials found no benefit.2-4 In addition, data from the National Health Interview Survey show that most people undergoing screening for lung cancer do not fall in the recommended groups, and thus their harms of LDCT, including radiation exposure, will likely exceed the benefits.5
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
I would be interested in a similar shared decision making study with PSA testing. Based upon my own experience, the results would likely be as disappointing as with lung cancer screening.
Redberg RF. Failing Grade for Shared Decision Making for Lung Cancer Screening. JAMA Intern Med. 2018;178(10):1295–1296. doi:10.1001/jamainternmed.2018.3527
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: